HM Payson & Co. lowered its holdings in shares of Advanced Proteome Therapeutics Corp. (NYSE:APC) by 20.7% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 15,171 shares of the energy producer’s stock after selling 3,950 shares during the period. HM Payson & Co.’s holdings in Advanced Proteome Therapeutics Corp. were worth $741,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Fis Group Inc. bought a new position in Advanced Proteome Therapeutics Corp. during the third quarter worth about $107,000. FNY Partners Fund LP grew its holdings in Advanced Proteome Therapeutics Corp. by 2,900.0% during the second quarter. FNY Partners Fund LP now owns 3,000 shares of the energy producer’s stock worth $136,000 after purchasing an additional 2,900 shares during the period. Sun Life Financial INC grew its holdings in Advanced Proteome Therapeutics Corp. by 1,363.4% during the second quarter. Sun Life Financial INC now owns 3,000 shares of the energy producer’s stock worth $136,000 after purchasing an additional 2,795 shares during the period. YorkBridge Wealth Partners LLC grew its holdings in Advanced Proteome Therapeutics Corp. by 12.5% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,606 shares of the energy producer’s stock worth $166,000 after purchasing an additional 402 shares during the period. Finally, Pier 88 Investment Partners LLC grew its holdings in Advanced Proteome Therapeutics Corp. by 537.1% during the third quarter. Pier 88 Investment Partners LLC now owns 4,033 shares of the energy producer’s stock worth $197,000 after purchasing an additional 3,400 shares during the period.

Shares of Advanced Proteome Therapeutics Corp. (NYSE APC) traded down C$0.29 during trading hours on Friday, hitting C$51.11. 5,000,000 shares of the stock traded hands, compared to its average volume of 5,770,000. Advanced Proteome Therapeutics Corp. has a 52 week low of C$39.96 and a 52 week high of C$73.33.

Advanced Proteome Therapeutics Corp. (NYSE:APC) last announced its quarterly earnings results on Tuesday, October 31st. The energy producer reported C($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.56) by C($0.21). The company had revenue of C$2.50 billion for the quarter, compared to analyst estimates of C$2.52 billion. Advanced Proteome Therapeutics Corp. had a negative return on equity of 25.27% and a negative net margin of 24.56%. The firm’s quarterly revenue was up 31.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.89) earnings per share.

Advanced Proteome Therapeutics Corp. declared that its Board of Directors has initiated a stock repurchase program on Wednesday, September 20th that authorizes the company to buyback $2.50 billion in shares. This buyback authorization authorizes the energy producer to purchase up to 10% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: “Advanced Proteome Therapeutics Corp. (APC) Shares Sold by HM Payson & Co.” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/12/advanced-proteome-therapeutics-corp-apc-shares-sold-by-hm-payson-co.html.

A number of research firms recently commented on APC. Scotiabank reiterated a “buy” rating and set a $62.00 price target on shares of Advanced Proteome Therapeutics Corp. in a report on Wednesday, November 1st. Stifel Nicolaus reduced their price objective on Advanced Proteome Therapeutics Corp. from $73.00 to $72.00 and set a “buy” rating for the company in a report on Wednesday, November 1st. Morgan Stanley set a $55.00 price objective on Advanced Proteome Therapeutics Corp. and gave the stock a “hold” rating in a report on Wednesday, October 18th. Cowen and Company set a $60.00 price objective on Advanced Proteome Therapeutics Corp. and gave the stock a “buy” rating in a report on Monday, October 16th. Finally, Wolfe Research cut Advanced Proteome Therapeutics Corp. from an “outperform” rating to a “market perform” rating in a report on Monday, October 16th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of C$66.77.

Advanced Proteome Therapeutics Corp. Company Profile

Anadarko Petroleum Corporation (Anadarko) is an independent exploration and production company. The Company is engaged in developing, acquiring, and exploring for oil and natural-gas resources. The Company’s segments include Oil and Gas Exploration and Production; Midstream, and Marketing. The Company’s geographical segments include the United States and International.

Institutional Ownership by Quarter for Advanced Proteome Therapeutics Corp. (NYSE:APC)

Receive News & Ratings for Advanced Proteome Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Proteome Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.